Quantcast
Last updated on April 17, 2014 at 16:08 EDT

Latest BioDelivery Sciences Stories

2014-01-10 08:23:03

BEMA Buprenorphine Phase 3 opioid naive study database lock imminent; triggers $10M milestone payment from Endo Pharmaceuticals RALEIGH, N.C., Jan. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced updates to the company's anticipated 2014 milestones for its product portfolio, including the imminent database lock for the Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain in opioid naive subjects, with...

2013-11-12 16:26:57

BUNAVAIL NDA Filed; PDUFA date June 7, 2014 RALEIGH, N.C., Nov. 12, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for 2013 and 2014. (Logo:...

2013-08-09 08:24:34

BUNAVAIL NDA submitted to FDA; first buccal film to compete in growing opioid dependence marketplace RALEIGH, N.C., Aug. 9, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an update on business operations and upcoming milestones for...